Background: Vitiligo is the most common chronic acquired depigmenting disorder, resulting  from  the  loss  of melanocytes   from   the   basal   epidermal  layer . Ecad  is  the  major  adhesion molecule   mediating   melanocyte–keratinocyte   interactions and is  essential  for  both  the  establishment  of  epithelial structures  during  development  and  numerous  dynamic  pro-cesses  such  as  differentiation,  polarity,  proliferation,  and migration   during   morphogenesis   and   homeostasis. The  aim of this work : is  to estimate the level of E- cadherin in serum of vitiligo patients before and after NB-UVB therapy as compared to normal control persons, to evaluate the role of E-cadherin in the pathogenesis of  this disease . Patients and methods: The level of E-cadherin was detected in 30 venous blood samples of vitiligo patients before (group I) and after treatment with NB-UVB ( group II) and 30 healthy controls  using  ELISA. Informe consent was obtained from the participants in this study after ethical committee approval from Dermatology Department of Medicine, Beni Suef  University . Results: Serum level of E- cadherin was significantly higher in vitiligo patients before exposure to narrow band UVB compared to healthy controls and became lower in vitiligo patients after exposure to narrow band UVB but still higher than control. No detected relation was found between serum level of E- cadherin and patients' age, skin type, symmetry ,vitiligo type ,last time of new lesions and VIDA (p-value >0.05). In addition, Serum Level of E-cadherin was significantly higher in Vitiligo patients with negative as compared with positive family history; with a statistically significant (p-value= 0.045),and slight negative significant linear correlation between serum level of E-cadherin and percentage of vitiligo in studied Vitiligo patients; (p=0.045). Coclusion :E- cadherin may play arole in the pathogenesis of vitiligo. Recommendations: On the basis of our findings in this study and in conjunction with that from previous studies, we suggest that: 1) Additional studies on large number of cases in association with assessment of E-cadherin  to evaluate its exact role in vitiligo pathogenesis. 2) Study gene polymorphism of E-cadherin gene and association with vitiligo. 3) Performing experimental study to evaluate the effect of E- cadherin up-regulation on vitiligo patients' response to NB-UVB and other modalities of therapy.